The Probe-lem Solved? The Road Toward an In Vivo, ATP-competitive CK2 Chemical Probe

The complexity of casein kinase 2 (CK2/CSNK2; encoded by CSNK2A1, CSNK2A2, and CSNK2B) and its regulatory roles across numerous cellular pathways both underscores its broad therapeutic potential and complicates efforts to define the contexts in which CK2 inhibition may be clinically beneficial. Accordingly, the development of high-quality chemical probes remains essential for elucidating CK2 biology. Since 2023, substantial progress has been made toward identifying potent, selective, and pharmacologically relevant CK2 inhibitors. Here, we summarize recent advances in ATP-competitive CK2 inhibitor development, with particular emphasis on cellular activity, kinome-wide selectivity, pharmacokinetic properties, and suitability for in vivo studies. We discuss the optimization of established monovalent chemotypes, including the pyrazolo[1,5-a]pyrimidine scaffold exemplified by SGC-CK2-1, as well as emerging scaffolds and bivalent inhibitor derivatives. Among the inhibitors discussed, APL-5125 has notably progressed toward an in vivo CK2 probe based on its single-digit nanomolar potency, excellent kinome-wide selectivity, and favorable in vivo properties that have supported its advancement into Phase 1/2 clinical trials. We conclude by outlining future directions for probe-enabled interrogation of CK2 biology.

Authors

Publication Details

Journal
Preprints.org
Published
2026-11-18
DOI
https://doi.org/10.20944/preprints202611.1928.v1
Primary Topic
Protein Kinase Regulation and GTPase Signaling
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

The Probe-lem Solved? The Road Toward an In Vivo, ATP-competitive CK2 Chemical Probe

Alison Axtman, Ross H. Sibley
Preprints.org
Protein Kinase Regulation and GTPase Signaling
preprint

The Probe-lem Solved? The Road Toward an In Vivo, ATP-competitive CK2 Chemical Probe

Alison Axtman, Ross H. Sibley
preprint en

Abstract

The complexity of casein kinase 2 (CK2/CSNK2; encoded by CSNK2A1, CSNK2A2, and CSNK2B) and its regulatory roles across numerous cellular pathways both underscores its broad therapeutic potential and complicates efforts to define the contexts in which CK2 inhibition may be clinically beneficial. Accordingly, the development of high-quality chemical probes remains essential for elucidating CK2 biology. Since 2023, substantial progress has been made toward identifying potent, selective, and pharmacologically relevant CK2 inhibitors. Here, we summarize recent advances in ATP-competitive CK2 inhibitor development, with particular emphasis on cellular activity, kinome-wide selectivity, pharmacokinetic properties, and suitability for in vivo studies. We discuss the optimization of established monovalent chemotypes, including the pyrazolo[1,5-a]pyrimidine scaffold exemplified by SGC-CK2-1, as well as emerging scaffolds and bivalent inhibitor derivatives. Among the inhibitors discussed, APL-5125 has notably progressed toward an in vivo CK2 probe based on its single-digit nanomolar potency, excellent kinome-wide selectivity, and favorable in vivo properties that have supported its advancement into Phase 1/2 clinical trials. We conclude by outlining future directions for probe-enabled interrogation of CK2 biology.

Preprints.org
Protein Kinase Regulation and GTPase Signaling
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon